Stock Financial Ratios, Dividends, Split History

SFN / Stifel Financial Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price25.11
Volume7,000.00
Market Cap ($M)1,796.82
Enterprise Value ($M)2,361.68
Book Value ($M)2,917.54
Book Value / Share40.77
Price / Book0.62
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 68,562,000
Common Shares Outstanding 71,850,904
Weighted Average Number Of Diluted Shares Outstanding 81,035,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.01
Return on Equity (ROE)0.07
Balance Sheet (mrq) ($M)
Assets21,715.34
Liabilities18,797.80
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Principal Transactions Revenue396,826,000.00
Brokerage Commissions Revenue678,904,000.00
Revenues2,996,462,000.00
Other Revenues0.00
Other Revenue From Contracts With Customer0.00
Investment Banking Revenue726,763,000.00
Revenues Excluding Interest And Dividends2,926,432,000.00
Net Income182.87
Earnings Per Share Diluted2.14
Earnings Per Share Basic2.53
Cash Flow Statement (mra) ($M)
Cash From Operations662.35
Cash from Investing-2,647.38
Cash from Financing662.35
Identifiers and Descriptors
CUSIP848420105
Central Index Key (CIK)720672

Split History

Stock splits are used by Stifel Financial Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

MOVES-Stifel hires Oppenheimer's Derek Archila as director, senior analyst

1h reuters
(Reuters) - Stifel Financial Corp (SF.N) said Derek Archila has joined the financial services company as a director and senior analyst, covering the biotechnology sector.

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2018 Update

3h seekingalpha
Amazon.com, Visa Inc., Apple Inc., Alibaba Group Holdings, and Microsoft are the largest five individual stock positions. (188-0)

MOVES- MUFG, KBW, Ernst & Young, Willis Towers

2018-07-16 reuters
July 16 (Reuters) - The following financial services industry appointments were announced on Monday. To inform us of other job changes, email [email protected]

MOVES-KBW hires Evercore's Rajib Sarkar as managing director

2018-07-16 reuters
(Reuters) - Keefe, Bruyette & Woods Inc, a subsidiary of Stifel Financial Corp (SF.N), said Rajib Sarkar has joined the broker-dealer as managing director in the insurance investment banking group.

Moving Average Crossover Alert: Stifel Financial (SF)

2018-07-16 zacks
Stifel Financial Corp. (SF - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for SF broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. (3-0)

CUSIP: 848420105